Literature DB >> 9118285

The effect of thymic function on immunocompetence following bone marrow transplantation.

K Weinberg1, G Annett, A Kashyap, C Lenarsky, S J Forman, R Parkman.   

Abstract

We investigated the role of thymic function in the immunodeficiency that characterizes bone marrow transplantation (BMT) recipients. The capacity of histocompatible BMT recipients to generate new CD4+ T lymphocytes was determined by FACS analysis with antibodies to the two isoforms of CD45: CD45RA, which is expressed on newly generated CD4 T lymphocytes, and CD45RO, which is expressed on antigen-specific memory CD4 T lymphocytes. Immediately following BMT, all patients had low levels of CD45RA-expressing CD4 T lymphocytes, which increased during the first year and then stabilized. Since thymic function decreases with age in normal individuals, the impact of recipient age on the generation of new CD45RA,CD4 T lymphocytes was determined in BMT recipients with and without chronic graft-vs.-host disease (GVHD). In addition, antigen-specific immune function was determined by assessing in vitro blastogenic response to tetanus toxoid (TT). More than 1 year after transplantation, the results from BMT recipients without chronic GVHD were similar to those of normal individuals; there was an age-dependent decline in the number of CD45RA,CD4 T lymphocytes, and antigen-specific immune function was age-independent. On the other hand, recipients with chronic GVHD had an age-dependent decline in their immune function (r = 0.45 and p = 0.02) that correlated with the number of new CD45RA,CD4 T lymphocytes (p = 0.027) but not the number of memory CD45RO,CD4 T lymphocytes (p = 0.11). Thus recipients with chronic GVHD have decreased antigen-specific immune function that may be due to an acceleration of the normal thymic aging process induced by GVHD and its therapy.

Entities:  

Mesh:

Year:  1995        PMID: 9118285

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  27 in total

1.  High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.

Authors:  Peter A McSweeney; Richard A Nash; Keith M Sullivan; Jan Storek; Leslie J Crofford; Roger Dansey; Maureen D Mayes; Kevin T McDonagh; J Lee Nelson; Theodore A Gooley; Leona A Holmberg; C S Chen; Mark H Wener; Katherine Ryan; Julie Sunderhaus; Ken Russell; John Rambharose; Rainer Storb; Daniel E Furst
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

Review 2.  Strategies for reconstituting and boosting T cell-based immunity following haematopoietic stem cell transplantation: pre-clinical and clinical approaches.

Authors:  Ann P Chidgey; Natalie Seach; Jarrod Dudakov; Maree V Hammett; Richard L Boyd
Journal:  Semin Immunopathol       Date:  2008-11-04       Impact factor: 9.623

3.  Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation.

Authors:  Hiroto Inaba; Christine M Hartford; Deqing Pei; Meredith J Posner; Jie Yang; Randall T Hayden; Ashok Srinivasan; Brandon M Triplett; Jon A McCulllers; Ching-Hon Pui; Wing Leung
Journal:  Br J Haematol       Date:  2011-10-24       Impact factor: 6.998

4.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

5.  CD4+ T cell-depleted lymphocyte infusion impairs neither the recovery of recipient thymus nor the development of transplanted thymus.

Authors:  Ming Shi; Ming Li; Yunze Cui; Lin Liu; Yasushi Adachi; Susumu Ikehara
Journal:  J Immunol       Date:  2013-02-04       Impact factor: 5.422

6.  Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques.

Authors:  Ruth Seggewiss; Karin Loré; F Javier Guenaga; Stefania Pittaluga; Joseph Mattapallil; Catherine K Chow; Richard A Koup; Kevin Camphausen; Martha C Nason; Martin Meier-Schellersheim; Robert E Donahue; Bruce R Blazar; Cynthia E Dunbar; Daniel C Douek
Journal:  Blood       Date:  2007-03-20       Impact factor: 22.113

Review 7.  Greater than the sum of their parts: combination strategies for immune regeneration following allogeneic hematopoietic stem cell transplantation.

Authors:  Jarrod A Dudakov; Marcel R M van den Brink
Journal:  Best Pract Res Clin Haematol       Date:  2011-06-29       Impact factor: 3.020

Review 8.  Thymus: the next (re)generation.

Authors:  Mohammed S Chaudhry; Enrico Velardi; Jarrod A Dudakov; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2016-05       Impact factor: 12.988

Review 9.  Hematopoietic stem cells for cancer immunotherapy.

Authors:  Eric Gschweng; Satiro De Oliveira; Donald B Kohn
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

10.  The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.

Authors:  Il-Kang Na; Sydney X Lu; Nury L Yim; Gabrielle L Goldberg; Jennifer Tsai; Uttam Rao; Odette M Smith; Christopher G King; David Suh; Daniel Hirschhorn-Cymerman; Lia Palomba; Olaf Penack; Amanda M Holland; Robert R Jenq; Arnab Ghosh; Hien Tran; Taha Merghoub; Chen Liu; Gregory D Sempowski; Melissa Ventevogel; Nicole Beauchemin; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.